Author: Kalfaoglu, Bahire; Almeida-Santos, José; Tye, Chanidapa Adele; Satou, Yorifumi; Ono, Masahiro
Title: T-cell dysregulation in COVID-19 Cord-id: zgujsi9c Document date: 2020_11_7
ID: zgujsi9c
Snippet: T-cells play key roles in immunity to COVID-19 as well as the development of severe disease. T-cell immunity to COVID-19 is mediated through differentiated CD4(+) T-cells and cytotoxic CD8(+) T-cells, although their differentiation is often atypical and ambiguous in COVID-19 and single cell dynamics of key genes need to be characterized. Notably, T-cells are dysregulated in severe COVID-19 patients, although their molecular features are still yet to be fully revealed. Importantly, it is not clea
Document: T-cells play key roles in immunity to COVID-19 as well as the development of severe disease. T-cell immunity to COVID-19 is mediated through differentiated CD4(+) T-cells and cytotoxic CD8(+) T-cells, although their differentiation is often atypical and ambiguous in COVID-19 and single cell dynamics of key genes need to be characterized. Notably, T-cells are dysregulated in severe COVID-19 patients, although their molecular features are still yet to be fully revealed. Importantly, it is not clear which T-cell activities are beneficial and protective and which ones can contribute to the development of severe COVID-19. In this article, we examine the latest evidence and discuss the key features of T-cell responses in COVID-19, showing how T-cells are dysregulated in severe COVID-19 patients. Particularly, we highlight the impairment of FOXP3 induction in CD4(+) T-cells and how the impaired FOXP3 expression can lead to the differentiation of abnormally activated (hyperactivated) T-cells and the dysregulated T-cell responses in severe patients. Furthermore, we characterise the feature of hyperactivated T-cells, showing their potential contribution to T-cell dysregulation and immune-mediated tissue destruction (immunopathology) in COVID-19.
Search related documents:
Co phrase search for related documents- activation result and adaptive immune cell: 1
- activation result and adjacent cell: 1
- active induce and acute phase: 1
- active induce and acute phase induce: 1
- active sle systemic lupus erythematosus and lupus erythematosus: 1, 2, 3
- acute phase and adaptive immune cell: 1, 2
- acute phase and lupus erythematosus: 1, 2
- acute phase and lymph node: 1, 2, 3, 4, 5
- acute phase and lymphocyte subset: 1, 2, 3
- lupus erythematosus and lymph node: 1, 2
Co phrase search for related documents, hyperlinks ordered by date